Nab-Paclitaxel
Showing 1 - 25 of 3,408
Pancreatic Cancer Trial (TTX-030, nab-paclitaxel and gemcitabine, TTX-030, budigalimab, nab-paclitaxel and gemcitabine,
Not yet recruiting
- Pancreatic Cancer
- TTX-030, nab-paclitaxel and gemcitabine
- +2 more
- (no location specified)
Nov 3, 2023
TNBC Trial in Shanghai (PM8002, nab-paclitaxel)
Recruiting
- TNBC
- PM8002
- nab-paclitaxel
-
Shanghai, ChinaFudan University Shanghai Cancer Center
Jun 25, 2023
Pancreatic Adenocarcinoma Metastatic Trial in Nanjing (Penpulimab, Anlotinib, Nab paclitaxel)
Recruiting
- Pancreatic Adenocarcinoma Metastatic
- Penpulimab
- +3 more
-
Nanjing, Jiangsu, ChinaThe Affiliated Nanjing Drum Tower Hospital of Nanjing University
Sep 18, 2023
Breast Tumors Trial in Hangzhou (Sindilimab, Nab-paclitaxel, Lenvatinib)
Not yet recruiting
- Breast Neoplasms
- Sindilimab
- +2 more
-
Hangzhou, Zhejiang, ChinaZhejiangCH
Nov 17, 2023
Metastatic Pancreatic Cancer Trial in Washington (Gemcitabine, Nab paclitaxel, Proglumide Dose level 1)
Not yet recruiting
- Metastatic Pancreatic Cancer
- Gemcitabine
- +3 more
-
Washington, District of ColumbiaLombardi Comprehensive Cancer Center, Georgetown University
Aug 24, 2023
Metastatic Pancreatic Adenocarcinoma Trial in Shanghai (Ascorbate, Nab paclitaxel, Gemcitabine)
Recruiting
- Metastatic Pancreatic Adenocarcinoma
- Ascorbate
- +2 more
-
Shanghai, Shanghai, ChinaShanghai Cancer Center
Aug 29, 2023
Advanced Biliary Tract Cancer Trial (anlotinib+TQB2450+nab-paclitaxel+cisplatin)
Not yet recruiting
- Advanced Biliary Tract Cancer
- (no location specified)
Apr 2, 2023
Metastatic Pancreatic Cancer, Adenocarcinoma of the Pancreas Trial in Weiden (nab-paclitaxel and gemcitabine, gemcitabine mono
Completed
- Metastatic Pancreatic Cancer
- Adenocarcinoma of the Pancreas
- nab-paclitaxel and gemcitabine
- gemcitabine mono and nab-paclitaxel and gemcitabine
-
Weiden, GermanyKliniken Nordoberpfalz AG, Klinikum Weiden
Nov 21, 2022
Gastric Cancer, Peritoneal Metastases, Ascites, Malignant Trial in Hangzhou (Sintilimab in Combination With S-1/oxaliplatin With
Recruiting
- Gastric Cancer
- +2 more
- Sintilimab in Combination With S-1/oxaliplatin With nab-paclitaxel intraperitoneal infusion
- Blood samples, tumor biopsy specimens, ascites, and feces samples will be collected
-
Hangzhou, Zhejiang, ChinaZhejiang Cancer Hospital
Sep 18, 2023
Bladder Cancer Trial in Tianjin (Cadonilimab)
Recruiting
- Bladder Cancer
-
Tianjin, Tianjin, ChinaTianjin Medical University Second Hospital
Aug 23, 2023
Gastric Cancer, GastroEsophageal Cancer Trial in Wuhan (Albumin-bound Paclitaxel Plus SHR-1210 (PD-1 inhibitor), Albumin-bound
Active, not recruiting
- Gastric Cancer
- GastroEsophageal Cancer
- Albumin-bound Paclitaxel Plus SHR-1210 (PD-1 inhibitor)
- Albumin-bound Paclitaxel
-
Wuhan, Hubei, ChinaTongji hospital of Tongji Medical College, Huazhong University o
Jan 21, 2023
Triple-Negative Breast Cancer Trial in Shanghai (Camrelizumab plus Famitinib with/without nab-Palitaxel)
Not yet recruiting
- Triple-Negative Breast Cancer
- Camrelizumab plus Famitinib with/without nab-Palitaxel
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center Shanghai, China, 200032
Jan 2, 2023
Metastatic Pancreatic Cancer Trial in Washington (Gemcitabine, Nab paclitaxel, Proglumide Dose level 1)
Not yet recruiting
- Metastatic Pancreatic Cancer
- Gemcitabine
- +3 more
-
Washington, District of ColumbiaLombardi Comprehensive Cancer Center, Georgetown University
Apr 11, 2023
Uterine Cervical Tumors, Cancer of Cervix, Cervical Cancer Trial (Cadonilimab, Nab paclitaxel)
Not yet recruiting
- Uterine Cervical Neoplasms
- +5 more
- Cadonilimab
- Nab paclitaxel
- (no location specified)
Apr 9, 2023
Her-2 Negative Breast Cancer, HRR Gene Mutation Trial in Guangzhou (Camrelizumab, Fluzoparib, Nab-paclitaxel)
Recruiting
- Her-2 Negative Breast Cancer
- HRR Gene Mutation
- Camrelizumab
- +2 more
-
Guangzhou, Guangdong, ChinaFirst Affiliated Hospital, Sun Yat-Sen University
Mar 7, 2023
HR+/HER2- Breast Cancer Trial (Tucidinostat, nab-paclitaxel)
Not yet recruiting
- HR+/HER2- Breast Cancer
- Tucidinostat
- nab-paclitaxel
- (no location specified)
Nov 21, 2022
Pancreatic Cancer Trial in Boston, Philadelphia (Gemcitabine, Nab-paclitaxel, Paricalcitol)
Active, not recruiting
- Pancreatic Cancer
- Gemcitabine
- +3 more
-
Boston, Massachusetts
- +1 more
Jan 9, 2023
Pancreatic Acinar Cell Carcinoma, Pancreatic Adenocarcinoma, Pancreatic Adenosquamous Carcinoma Trial (Nab paclitaxel,
Not yet recruiting
- Pancreatic Acinar Cell Carcinoma
- +6 more
- Nab paclitaxel
- +5 more
- (no location specified)
Oct 30, 2023
Resectable Pancreatic Cancer, Ductal Adenocarcinoma of the Pancreas Trial in Ulm (perioperative nab-paclitaxel/gemcitabine,
Completed
- Resectable Pancreatic Cancer
- Ductal Adenocarcinoma of the Pancreas
- perioperative nab-paclitaxel/gemcitabine
- adjuvant nab-paclitaxel/gemcitabine
-
Ulm, GermanyUniversity of Ulm, Dept. of Internal Medicine I
Nov 21, 2022
Pancreatic Cancer, Stage IB, Pancreatic Cancer, Stage IIA, Pancreatic Cancer, Stage IIB Trial in Shanghai (sintilimab,
Not yet recruiting
- Pancreatic Cancer, Stage IB
- +3 more
- sintilimab
- +2 more
-
Shanghai, Shanghai, ChinaZhongshan Hospital
Jan 4, 2023
Solid Tumors Trial in United States (CORT125134 with nab-paclitaxel)
Completed
- Solid Tumors
- Relacorilant with nab-paclitaxel
-
Scottsdale, Arizona
- +3 more
Nov 9, 2022
Breast Cancer Trial in Haidian (nab-paclitaxel regimen1, nab-paclitaxel regimen2)
Active, not recruiting
- Breast Cancer
- nab-paclitaxel regimen1
- nab-paclitaxel regimen2
-
Haidian, Beijing, ChinaBeijingCancerH
Oct 11, 2022